Prophylaxis and treatment of hepatitis B recurrence after liver transplantation in the antiviral era

Expert Review of Anti-Infective Therapy

Volumn 1, Issue 2, 2003, Pages 307-318

  Seehofer, Daniel ^a   Rayes, Nada ^a   Neuhaus, Peter ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Active immunization; Adefovir dipivoxil; Antiviral treament; Combination theraphy; Hepatitis B; Hepatitis B immune globulin; Lamivudine; Liver transplantation; Prophylaxis; Resistance formation

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ANTIVIRUS AGENT; DNA POLYMERASE; ENTECAVIR; FAMCICLOVIR; GANCICLOVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; LAMIVUDINE; NUCLEOSIDE ANALOG; TENOFOVIR DISOPROXIL;

ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; GRAFT INFECTION; HEPATITIS B; HEPATITIS VIRUS; HUMAN; IMMUNOPROPHYLAXIS; LIVER FAILURE; LIVER TRANSPLANTATION; PREOPERATIVE CARE; RECURRENT INFECTION; REVIEW; TREATMENT OUTCOME; VIRION; VIRUS MUTATION;

EID: 3042699645     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.1.2.307     Document Type: Review

References (74)

1. Samuel D, Muller R, Alexander G et al. Liver transplantation in European patients with the hepatitis B surface antigen. N. Engl. J. Med. 329, 1842-1847 (1993).
2. Steinmüller T, Seehofer D, Rayes N et al. Increasing applicability of liver transplantation for patients with hepatitis B related liver disease. Hepatology 35, 1528-1535 (2002).
3. Anselmo DM, Ghobrial RM, Jung LC et al. New era of liver transplantation for hepatitis B: a 17 year single-center experience. Ann. Surg. 235, 611-620 (2002).
4. Feray C, Zignego AL, Samuel D et al. Persistent hepatitis B virus infection of mononuclear blood cells without concomitant liver infection. The liver transplantation model. Transplantation 49, 1155-1158 (1990).
5. Lauchart W, Müller R, Pichlmayer R, Long-term immunoprophylaxis of hepatitis B virus re-infection in recipients of human liver grafts. Transplant Proc. 19, 4051-4053 (1987).
6. Samuel D, Bismuth A, Mathieu D et al. Passive immunoprophylaxis after liver transplantation in HBsAg+ patients. Lancet 337, 813-815 (1991).
7. Gugenheim J, Baldini E, Ouzan D, Mouiel J. Absence of initial viral replication and long-term high dose immune globulin administration improve results of hepatitis B virus recurrence prophylaxis after liver transplantation. Transplant Proc. 29, 517-518 (1997).
8. Devlin J, Smith HM, O'Grady JG, Portmann B, Tan KC, Williams R. Impact of immunoprophylaxis and patient selection on outcome of transplantation for HBsAg positive liver recipients. J. Hepatol. 21, 204-210 (1994).
9. Nymann T, Shokouh-Amiri MH, Vera SR, Riely CA, Alloway RR, Gaber AO. Prevention of hepatitis B recurrence with indefinite hepatitis B immune globuloin (HBIg) prophylaxis after liver transplantation. Clin. Transplant. 10, 663-667 (1996).
10. Grazi GL, Mazziotti A, Sama C et al. Liver transplantation in HBsAg positive HBV-DNA negative cirrhotics: immunoprophylaxis and long term outcome. Liver Transpl. Surg. 2, 418-425 (1996).
11. Terrault NA, Zhou S, Combs C et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepititis B immune globulin. Hepatology 24, 1327-1333 (1996).
12. Tchervenkov JI, Tector AJ, Barkun JS et al. Recurrence free long-term survival after liver transplantation for hepatitis B using interferon-α pretransplant and hepatitis B immune globuline post-transplant. Ann. Surg. 226, 356-368 (1997).
13. Sawyer RG, McGory RW, Gaffey MJ et al. Improved clinical outcome with liver transplantation for hepatitis B-induced chronic liver failure using passive Immunization. Ann. Surg. 227, 841-850 (1998).
14. Lerut JP, Donataccio M, Ciccarelli O et al. Liver transplantation and HBsAg positive postnecrotic cirrhosis: adequate immunoprophylaxis and delta virus coinfection as the significant determinants of long-term prognosis. J. Hepatol. 30, 706-714 (1999).
15. Han SHB, Ofman J, Holt C et al. An efficacy and cost-effectivness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globuline monotherapy. Liver Transplant. 6, 741-748 (2000).
16. Chu CJ, Fontana RJ, Moore C et al. Outcome of liver transplantation for hepatitis B: report of a single center's experience. Liver Transplant. 7, 724-731 (2001).
17. Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 32, 1189-1195 (2000).
18. Burbach GJ, Bienzle U, Neuhaus R et al. Intravenous or intramuscular anti-HBs immunoglobulin for the prevention of hepatitis B reinfection after orthotopic liver transplantation. Transplantation 63, 478-480 (1997).
19. Ghany MG, Ayola B, Villamil FG et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 27, 213-222 (1998).
20. Protzer-Knolle U, Naumann U, Bartenschlager R et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 27, 254-263 (1998).
21. Chalasani N, Smallwood G, Halcomb J, Fried MW, Boyer TD. Is vaccination against hepatitis B infection indicated in patients waiting for or after orthotopic liver transplantation? Liver Transplant. Surg. 4, 128-132 (1998).
22. Sanchez-Fueyo A, Rimola A, Grande L et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: a new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 31, 496-501 (2000).
23. Angelico M, di Paolo D, Trinito MO et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 35, 176-181 (2002).
24. Bienzle U, Günther M, Neuhaus R, Neuhaus P. Successful hepatitis B vaccination in patients who underwent transplantation for hepatitis B virus-related cirrhosis: preliminary results. Liver Transplant 8, 562-564 (2002).
25. Lo CM, Fung JTK, Lau GKK et al. Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B. Hepatology 37, 36-43 (2003).
26. Grellier L, Mutimer D, Ahmed M et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 348, 1212-1215 (1996).
27. Mutimer D, Pillay D, Dragon E et al. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J. Hepatol. 30, 715-721 (1999).
28. Bain VG, Kneteman NM, Ma MM et al. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 62, 1456-1462 (1996).
29. Perillo RP, Wright T, Rakela J et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 33, 424-432 (2001).
30. Lo CM, Cheung ST, Lai CL et al. Liver transplantation in asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann. Surg. 233, 276-281 (2001).
31. Naoumov NV, Lopes AR, Burra P et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J. Hepatol. 34, 888-894 (2001).
32. Dodson SF, de Vera ME, Bonham A, Geller DA, Rakela J, Fung JJ. Lamivudine after hepatitis B immunglobulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transplant. 6, 434-439 (2000).
33. Locarnini S, Birch C. Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients. J. Hepatol. 30, 536-550 (1999).
34. Markowitz JS, Martin P, Conrad AJ et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 28, 585-589 (1998).
35. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transplant. 6, 429-433 (2000).
36. Marzano A, Salizzoni M, Debernardi-Venon W et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J. Hepatol, 34, 903-910 (2001).
37. Seehofer D, Rayes N, Steinmüller T et al. Combination prophylaxis with Hepatitis B immunoglobulin and lamivudine after liver transplantation minimizes HBV recurrence rates unless evolution of pretransplant lamivudine resistance. Z Gastroenterol. 40, 795-799 (2002).
38. Yoshida EM, Erb SR, Partovi N et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transplant. Surg. 1999, 5, 520-525.
39. Yao FY, Osorio RW, Roberts JP et al. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transplant. Surg. 5, 491-496 (1999).
40. Dodson F, de Vera ME, Bonham CA, Geller DA, Rakela J, Fung JJ. Lamivudine after hepatitis B immune globuline is effective in preventing hepatitis B recurrence after liver transplantatio. Liver Transplant. 6, 434-439 (2000).
41. Blum HE. Variants of hepatitis B, C and D viruses: molecular biology and clinical significance. Digestion 56, 85-95 (1995)
42. Hunt CM, McGill JM, Allen MI, Condereay. Clinical relevance of hepatitis B viral mutations. Hepatology 31, 1037-1044 (2000)
43. Naumann U, Protzer-Knolle U, Berg T et al. Pretransplant infection with precore mutants of hepatitis B virus does not influence the outcome of orthotopic liver transplantation in patients on high dose anti-hepatitis B virus surface antigen immunoprophylaxis. Hepatology 26, 478-484 (1997).
44. Angus PW, Locarnini SA, McCaughan GW, Jones RM, McMillan JS, Bowden DS. Hepatitis B virus precore mutant infection is associated with severe recurrent disease after liver transplantation. Hepatology 21, 14-18 (1995)
45. Brunetto MR, Giarin M, Saracco G et al. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology 105, 845-850 (1993).
46. Zoulim F, Trépo C. Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy. Hepatol. 29, 151-168 (1998).
47. Allen MI, Deslauriers M, Andrews CB et al. Identification and characterization of mutations in Hepatitis B virus resistant to lamivudine. Hepatology 27, 1670-1677 (1998).
48. Ona-Nita SK, Kato N, Shiratori Y et al. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: a study by in vitro full-length viral DNA transfection. Hepatology 29, 939-945 (1999).
49. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 27, 628-633 (1998).
50. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 120, 1828-1853 (2001).
51. Seehofer D, Rayes N, Berg T et al. Lamivudine as first- and second-line treatment of hepatitis B infection after liver transplantation. Transplant. Int. 13, 290-296 (2000).
52. Nery JR, Weppler D, Rodriguez M, Ruiz P, Schiff ER, Tzakis AG. Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation. Transplantation 65, 1615-1621 (1998)
53. Petrillo R, Rakela J, Dienstag J et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 29, 1581-1586 (1999).
54. Terrault NA. Treatment of recurrent hepatitis B infection in liver transplant recipients. Liver Transplant. 10(Suppl. 1), S74-S81 (2002).
55. Seehofer D, Rayes N, Steinmüller T et al. Occurence and clinical outcome of lamivudine resistant hepatitis B infection after liver transplantation. Liver Transplant. 7, 976-982 (2001).
56. Mutimer D, Pillay D, Shields P et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 46, 107-113 (2000).
57. Hopf U, Neuhaus P, Lobeck H, König V, Küther S et al. Follow up of recurrent hepatitis B and delta infection in liver allograft recipients after treatment with recombinant interferon. J. Hepatol. 13, 339-346 (1991).
58. Gish R, Lau J, Brooks L et al. Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients. Hepatology 23, 1-7 (1996).
59. Rayes N, Seehofer D, Bechstein WO et al. Long-term results of famciclovir for recurrent or de novo hepatitis B virus infection after liver transplantation. Clin. Transplant. 13, 447-452 (1999).
60. Seehofer D, Rayes N, Berg T et al. Additional interferon alpha for lamivudine resistant hepatitis-B infection after liver transplantation. Transplantation 69, 1739-1742 (2000).
61. Perrillo R, Schiff E, Yoshida E et al. Adefovir dipivoxil for the treatment of lamivudine resistant hepatitis B mutants. Hepatology 32, 129-134 (2000).
62. Schiff ER, Neuhaus P, Tillmann H et al. Safety and efficacy of adefavir dipivoxil for the treatment of lamivudine resistant HBV in patients post liver transplantation. Hepatology 34(Suppl), 1098 (2001) (Abstract).
63. Yang H, Westland CE, Delaney WE et al. Resistance surveillane in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 36, 464-473 (2002).
64. Honkoop P, de Man RA. Entecavir: a potent new antiviral drug for hepatitis B. Expert Opin. Investigat. Drugs 12, 683-688 (2003).
65. Lai CL, Rosmawati M, Lao J et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 123, 1831-1838 (2002).
66. Van Bömmel F, Wünsche T, Schürmann D, Berg T. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology 36, 507-508 (2002).
67. Seehofer D, Rayes N, Naumann U et al. Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation. Transplantation 72, 1381-1385 (2001).
68. Petrillo RP, Wright T, Rakela J et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 33, 424-432 (2001).
69. Bain VG, Kneteman-NM, Ma MM et al. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 62, 1456-1462 (1996).
70. McCaughan GW, Spencer J, Koorey D et al. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. Liver Transplant. 5, 512-519 (1999).
71. Sponseller CA, Bacon BR, Di Bisceglie AM. Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine. Liver Transplant. 6, 715-720 (2000).
72. Yao FY, Terrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is benifical in patients with severly decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 34, 411-416 (2001).
73. Fontana RJ, Keeffe EB, Carey W et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transplant. 8, 433-439 (2002).
74. Rosenau J, Bahr MJ, Tilmann HL et al. Lamivudine and low-dose hepatitis B immune globuline for prophylaxis of hepatitis B reinfection after liver transplantation - possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J. Hepatology 34, 895-902 (2001).